

## **REMARKS**

### **Claim Status and Amendments**

Claims 1-10, 12, 13 and 15-31 are pending. Claims 1-10, 12, 13 and 15 are rejected. Claim 16 is allowed. Claims 17-31 are withdrawn from consideration. Claims 1, 4, 13, 25, 26 and 30 are amended herein.

Claim 1 has been amended to recite "[an] isolated artificial peptide mimic." Support for the recitation "artificial" can be found at page 14, lines 28-31 of the specification and throughout the Sequence Listing.

Claim 13 has been amended to delete the recitation "antigen-binding" and to replace "monoclonal antibodies" with the "a monoclonal antibody."

Claims 4, 13, 25, 26 and 30 have been amended to eliminate multiply dependent claims depending upon multiply dependent claims and dependencies on cancelled claims.

No new matter has been added.

### **Objection to the Drawings**

Replacement Drawings, which incorporate the Amendments to the Drawings made August 26, 2003, are being submitted herewith. Applicants believe that the Replacement Drawings address all informalities noted in the drawings. Withdrawal of the objection is respectfully requested.

### **Rejections Withdrawn**

Applicants acknowledge, with appreciation, the Examiner's withdrawal of various prior claim rejections under 35 U.S.C. § 112, second paragraph, as well as under 35 U.S.C. §§ 102(b) and 103(a).

### **New or Modified Rejections**

#### **Rejection of Claim 13 and Those Dependent Therefrom Under 35 U.S.C. § 112, First Paragraph**

Claim 13 and those dependent therefrom are rejected under 35 U.S.C. § 112, first paragraph, "as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention." The Examiner contends that the recitation "antigen-binding" constitutes new matter.

In order to expedite allowance of this application, applicants have deleted the phrase "antigen-binding" from the claims, thereby obviating the rejection. Nevertheless, applicants maintain that the deleted phrase is supported by the specification and that those of skill in the art would appreciate that the recited fragments are inherently antigen-binding, based upon the context of the claims. Withdrawal of the rejection is respectfully requested.

Rejection of Claims 13 and 15 Under 35 U.S.C. § 112, Second Paragraph

Claims 13 and 15 are rejected under 35 U.S.C. § 112, second paragraph, "as indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention." The Examiner contends that claim 13 is "vague, indefinite and confusing" in the limitation hybridoma cell lines having the specific immunological reactivity of monoclonal antibodies produced by hybridoma cell line HB 11311 as deposited with the ATCC. The Examiner questions whether the recitation means that the recited hybridoma cell line produces more than one type of monoclonal antibodies.

Applicants believe that the claim is clear as written because one skilled in the art would understand that a hybridoma generally only produces one type of monoclonal antibody. Accordingly, use of the plural "monoclonal antibodies" would be interpreted by one skilled in the art to mean that the hybridoma produces multiple copies of antibodies and not multiple types of antibodies. Nevertheless, applicants have amended claim 13 to replace the phrase "monoclonal antibodies" with --a monoclonal antibody--. Reconsideration and withdrawal of the rejection are respectfully requested.

Rejection of Claims 1-3, 10, 12, 13 and 15 Under 35 U.S.C. § 102(b)

Claims 1-3, 10, 12, 13 and 15 are rejected under 35 U.S.C. § 102(b) as anticipated by Kufer *et al* (WO 98/46645).

Claim 1, upon which claims 2-3, 10, 12, 13 and 15 depend, has been amended to recite that the claimed isolated peptide mimic is an *artificial* peptide mimic. In contrast, the peptide disclosed by Kufer *et al.* is a *human* peptide mimic. See, for example, Example V on pages 39-40 of Kufer *et al.* Thus, the claimed peptide mimics are novel over Kufer *et al.* Reconsideration and withdrawal of the rejection are respectfully requested.

Rejection of Claims 4-9 Under 35 U.S.C. § 103(a)

Claims 4-9 are rejected under 35 U.S.C. § 103(a) over Kufer *et al.*, in view of Huang *et al.* (*Mol. Immunol.* 31: 1191-1199, 1994) and Tam (in *Peptide Antigens: A Practical Approach*. G.B. Wisdom (Ed.). IRL Press, Oxford University Press, New York, pp. 83-90, 1994). The Examiner asserts that it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to modify Kufer *et al.*'s peptide as a multiple antigen peptide, in view of Huang *et al.* and Tam. However, as discussed above, Kufer *et al.* do not teach the claimed artificial peptide mimics. Thus, even if Kufer *et al.* is combined with Huang *et al.* and Tam, the result does not teach or suggest the peptide mimics of applicants' claims. Therefore, claims 4-9 are not *prima facie* obvious over the cited art. Reconsideration and withdrawal of the rejection are respectfully requested.

CONCLUSION

Applicants request that the Examiner enter the amendments and consider the foregoing remarks and pass the application to issue.

Dated: June 21, 2006

Respectfully submitted,

By Jesse A. Fecker  
Margaret A. Pierri (Registration No.: 30,709)  
Jesse A. Fecker, Ph.D. (Registration No.: 52,883)  
FISH & NEAVE IP GROUP,  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020  
(212) 596-9000  
(212) 596-9090 (Fax)  
Attorneys/Agents For Applicants